Home » Stocks » CFRX

ContraFect Corporation (CFRX)

Stock Price: $5.41 USD -0.01 (-0.18%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $5.27 -0.14 (-2.59%) Jan 26, 7:57 PM
Market Cap 150.73M
Revenue (ttm) n/a
Net Income (ttm) -32.11M
Shares Out 27.81M
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $5.41
Previous Close $5.42
Change ($) -0.01
Change (%) -0.18%
Day's Open 5.49
Day's Range 5.32 - 5.49
Day's Volume 168,849
52-Week Range 4.69 - 11.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 months ago

CARB-X and Cystic Fibrosis Foundation grant s provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections

GlobeNewsWire - 3 months ago

YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (D...

GlobeNewsWire - 4 months ago

YONKERS, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic ...

GlobeNewsWire - 5 months ago

Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis In...

GlobeNewsWire - 5 months ago

Exebacase Phase 2 study results published in the Journal of Clinical Investigation

GlobeNewsWire - 6 months ago

YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agen...

GlobeNewsWire - 7 months ago

Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia

GlobeNewsWire - 7 months ago

YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic ag...

GlobeNewsWire - 8 months ago

YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for th...

GlobeNewsWire - 8 months ago

YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for th...

GlobeNewsWire - 8 months ago

YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (...

GlobeNewsWire - 8 months ago

Abstracts highlight the advancement of three new antibacterial modalities: novel native lysins, engineered lysins and amurin peptides Abstracts highlight the advancement of three new antibacte...

GlobeNewsWire - 9 months ago

YONKERS, N.Y., March 30, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

GlobeNewsWire - 10 months ago

YONKERS, N.Y., March 18, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

GlobeNewsWire - 11 months ago

YONKERS, N.Y., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic ag...

Seeking Alpha - 11 months ago

ContraFect: A Game-Changing Treatment For The Superbug MRSA

GlobeNewsWire - 11 months ago

YONKERS, N.Y., Feb. 04, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic ag...

GlobeNewsWire - 11 months ago

YONKERS, N.Y., Feb. 03, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic ag...

Seeking Alpha - 1 year ago

ContraFect Corporation Is A Differentiated Infectious Disease Pick For 2020

GlobeNewsWire - 1 year ago

YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic ag...

GlobeNewsWire - 1 year ago

Superiority Trial to Confirm Significantly Improved Clinical Outcomes with Exebacase Added to Antibiotics versus Antibiotics alone to treat Methicillin-Resistant Staph aureus (MRSA) Bacteremia...

GlobeNewsWire - 1 year ago

Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potential Targeted Therapeutic for serious infections caused by multi-drug resistant P. aeruginosa Pre-Clinical Data Demonstrate Ef...

GlobeNewsWire - 1 year ago

YONKERS, N.Y., Dec. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for t...

GlobeNewsWire - 1 year ago

YONKERS, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for t...

GlobeNewsWire - 1 year ago

Primary Endpoint of Clinical Response at Day 14 in Patients with Methicillin-Resistant Staph aureus ( MRSA) Bacteremia, including Right-Sided Endocarditis

GlobeNewsWire - 1 year ago

YONKERS, N.Y., Sept. 26, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic a...

GlobeNewsWire - 1 year ago

YONKERS, New York, Sept. 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lyt...

GlobeNewsWire - 1 year ago

YONKERS, N.Y., Aug. 28, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic ag...

About CFRX

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineere... [Read more...]

Industry
Biotechnology
IPO Date
Jul 29, 2014
CEO
Roger Pomerantz
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
CFRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ContraFect stock is "Strong Buy." The 12-month stock price forecast is 17.75, which is an increase of 228.10% from the latest price.

Price Target
$17.75
(228.10% upside)
Analyst Consensus: Strong Buy